Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 10/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19051472 | 0.88 | SLC6A5 (0.39) | — | |
| SCHEMBL18796598 | 0.87 | HDAC6 (0.54) | HDAC6HDAC1 | |
| SCHEMBL27926541 | 0.87 | HDAC6 (0.54) | HDAC6HDAC1 | |
| SCHEMBL2471870 | 0.86 | OPRK1 (0.40) | HDAC6HDAC1MEN1KMT2A | |
| SCHEMBL2471875 | 0.86 | OPRK1 (0.40) | HDAC6HDAC1MEN1KMT2A | |
| SCHEMBL18381363 | 0.86 | MMP1 (0.43) | HDAC6HDAC1 | |
| SCHEMBL19451083 | 0.85 | HDAC6 (0.48) | HDAC6HDAC1MEN1HCRTR1KMT2A | |
| SCHEMBL26080391 | 0.85 | PTPN1 (0.37) | HDAC6HDAC1 | |
| SCHEMBL2597834 | 0.85 | HDAC6 (0.48) | HDAC6HDAC1MEN1HCRTR1KMT2A | |
| SCHEMBL18381353 | 0.85 | PTPN1 (0.37) | HDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183318-A1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES | ACE, ACE2, MCTS1 | HDAC6 201/4885HDAC1 200/4885MEN1 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.